{"protocolSection":{"identificationModule":{"nctId":"NCT00192036","orgStudyIdInfo":{"id":"8984"},"secondaryIdInfos":[{"id":"B9E-BX-JHSQ","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer","officialTitle":"Multicenter Phase II Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2010-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-08"},"primaryCompletionDateStruct":{"date":"2008-01","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-12","studyFirstSubmitQcDate":"2005-09-12","studyFirstPostDateStruct":{"date":"2005-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-02-23","resultsFirstSubmitQcDate":"2009-02-23","resultsFirstPostDateStruct":{"date":"2009-03-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-11-22","lastUpdatePostDateStruct":{"date":"2010-12-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate the response rate of patients with non small lung cancer to gemcitabine in combination with radiotherapy. The tolerability and safety of this combination will also be evaluated."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":49,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Gemcitabine + Cisplatin","type":"EXPERIMENTAL","description":"Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, IV, every 21 days x 5 cycles.\n\nRadiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5.","interventionNames":["Drug: gemcitabine","Drug: cisplatin","Radiation: radiation"]}],"interventions":[{"type":"DRUG","name":"gemcitabine","description":"1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)","armGroupLabels":["Gemcitabine + Cisplatin"],"otherNames":["LY188011","Gemzar"]},{"type":"DRUG","name":"cisplatin","description":"80 mg/m2, IV, every 21 days x 5 cycles","armGroupLabels":["Gemcitabine + Cisplatin"]},{"type":"RADIATION","name":"radiation","description":"63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5","armGroupLabels":["Gemcitabine + Cisplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Tumor Response at End of Treatment","description":"Response recorded at the first follow-up visit using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.","timeFrame":"baseline to first follow-up visit (up to 8 weeks after end of chemo-radiation)"}],"secondaryOutcomes":[{"measure":"Time to Progressive Disease","description":"Time to progressive disease is the time from the date of enrollment to the first date of documented disease progression. Patients who have not had disease progression will be censored at the date of the last follow-up visit. Patients dying because of reasons other than tumor progression are not included.","timeFrame":"Preliminary: baseline to measured progressive disease (up to 3.5 years); Final: baseline to measured progressive disease (up to 5 years);"},{"measure":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.","timeFrame":"Preliminary: baseline to date of death from any cause (up to 3.5 years); Final: baseline to date of death from any cause (up to 5 years)"},{"measure":"Safety of Induction Chemotherapy","description":"A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading scales. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant Grade 3 and Grade 4 toxicities occurring during induction chemotherapy are reported. Grade 3 events are severe and Grade 4 events are life-threatening.","timeFrame":"every cycle (21 days) for 3 cycles (up to 10 weeks)"},{"measure":"Safety of Chemo-radiotherapy","description":"A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to NCI-CTC Version 2.0 grading scales. For specific radiation events, Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation toxicity scale was used. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant acute Grade 3 and Grade 4 toxicities (worst severity) occurring during chemo-radiation and up to 49 days (8 weeks) after are reported. Grade 3 events are severe and Grade 4 events are life-threatening.","timeFrame":"Cycles 4 and 5 up to 8 weeks after the end of chemo-radiotherapy"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inoperable non small cell lung cancer Stage III\n* Adequate hematological parameters\n* Adequate Lung function reserve\n\nExclusion Criteria:\n\n* Previous chemotherapy and thoracic radiation for non small cell lung cancer\n* Presence of distant metastases","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aalst","zip":"9300","country":"Belgium","geoPoint":{"lat":50.93604,"lon":4.0355}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Charleroi","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gilly","zip":"6060","country":"Belgium","geoPoint":{"lat":50.42449,"lon":4.4789}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Haine-St.- Paul","zip":"7100","country":"Belgium"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Herentals","zip":"2200","country":"Belgium","geoPoint":{"lat":51.17655,"lon":4.83248}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mechelen","zip":"2800","country":"Belgium","geoPoint":{"lat":51.02574,"lon":4.47762}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ottignies","zip":"1340","country":"Belgium","geoPoint":{"lat":50.66535,"lon":4.56679}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Turnhout","zip":"2300","country":"Belgium","geoPoint":{"lat":51.32254,"lon":4.94471}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"49"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"28"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"21"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"Patient/Physician Perception","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Objective Tumor Progression","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Clinical Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]},{"type":"Unknown or Not Specified","reasons":[{"groupId":"FG000","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"49"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.1","spread":"8.41"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"13"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"36"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"49"}]}]}]},{"title":"Basis for Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Histopathological","categories":[{"measurements":[{"groupId":"BG000","value":"39"}]}]},{"title":"Cytological","categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}]}]},{"title":"Disease Stage","description":"Stage means how big the tumor is and how far it has spread. Stages range from 0 (not spread) to IV (spread throughout the body). Stage IIIA - the cancer has spread to nearby tissue or spread to near by lymph nodes. Stage IIIB - cancer spread to opposite side of chest, more than one tumor within same lobe of lung.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}]},{"title":"Stage IIIB","categories":[{"measurements":[{"groupId":"BG000","value":"35"}]}]}]},{"title":"Karnofsky Performance Status Scale","description":"Classifies patients according to their functional impairment. Scores range from 0-100, the lower the score, the worse the survival for most serious illnesses.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"80 - Activity with effort; some signs of disease","categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}]},{"title":"90 - Normal activity; minor signs of disease","categories":[{"measurements":[{"groupId":"BG000","value":"24"}]}]},{"title":"100 - Normal no complaints; no evidence of disease","categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}]}]},{"title":"Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma of Lung","categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}]},{"title":"Large Cell","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"Other Pathological Diagnosis","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"Squamous Cell","categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}]}]},{"title":"Time Since Diagnosis","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"months","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0.5","spread":"0.25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Tumor Response at End of Treatment","description":"Response recorded at the first follow-up visit using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.","populationDescription":"All enrolled participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"baseline to first follow-up visit (up to 8 weeks after end of chemo-radiation)","groups":[{"id":"OG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}]},{"type":"SECONDARY","title":"Time to Progressive Disease","description":"Time to progressive disease is the time from the date of enrollment to the first date of documented disease progression. Patients who have not had disease progression will be censored at the date of the last follow-up visit. Patients dying because of reasons other than tumor progression are not included.","populationDescription":"All enrolled participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Preliminary: baseline to measured progressive disease (up to 3.5 years); Final: baseline to measured progressive disease (up to 5 years);","groups":[{"id":"OG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"title":"Preliminary","categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"0.9","upperLimit":"39.2"}]}]},{"title":"Final","categories":[{"measurements":[{"groupId":"OG000","value":"11.4","lowerLimit":"9.4","upperLimit":"12.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.","populationDescription":"All enrolled participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"Preliminary: baseline to date of death from any cause (up to 3.5 years); Final: baseline to date of death from any cause (up to 5 years)","groups":[{"id":"OG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"title":"Preliminary","categories":[{"measurements":[{"groupId":"OG000","value":"27.9","lowerLimit":"0.9","upperLimit":"39.2"}]}]},{"title":"Final","categories":[{"measurements":[{"groupId":"OG000","value":"21.8","lowerLimit":"17.5","upperLimit":"26.0"}]}]}]},{"type":"SECONDARY","title":"Safety of Induction Chemotherapy","description":"A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 grading scales. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant Grade 3 and Grade 4 toxicities occurring during induction chemotherapy are reported. Grade 3 events are severe and Grade 4 events are life-threatening.","populationDescription":"All enrolled participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"every cycle (21 days) for 3 cycles (up to 10 weeks)","groups":[{"id":"OG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"title":"Neutropenia - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]},{"title":"Neutropenia - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Thrombocytopenia - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Thrombocytopenia - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Safety of Chemo-radiotherapy","description":"A grading (severity) scale is provided for each adverse event term. Toxicities were graded according to NCI-CTC Version 2.0 grading scales. For specific radiation events, Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation toxicity scale was used. Grades range from 0 (none) to 5 (death). Number of participants with clinically significant acute Grade 3 and Grade 4 toxicities (worst severity) occurring during chemo-radiation and up to 49 days (8 weeks) after are reported. Grade 3 events are severe and Grade 4 events are life-threatening.","populationDescription":"All enrolled participants receiving chemo-radiotherapy (Cycle 4).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Cycles 4 and 5 up to 8 weeks after the end of chemo-radiotherapy","groups":[{"id":"OG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, intravenous, day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).\n\nCisplatin: 80 mg/m2, intravenous, every 21 days x 5 cycles. Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"}]}],"classes":[{"title":"Neutropenia - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"Neutropenia - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Thrombocytopenia - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]},{"title":"Thrombocytopenia - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Radiation Esophagitis - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Radiation Esophagitis - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Radiation Pneumonitis - Grade 3","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Radiation Pneumonitis - Grade 4","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Gemcitabine + Cisplatin","description":"Gemcitabine: 1250 mg/m2, IV, day 1 and day 8 q 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5) Cisplatin: 80 mg/m2, IV, q 21 days x 5 cycles Radiation: 63 Gy in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5","seriousNumAffected":13,"seriousNumAtRisk":49,"otherNumAffected":48,"otherNumAtRisk":49}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":49}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":49}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":49}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":49}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Radiation oesophagitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":49}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":49}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Tracheal haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":49}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":49}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":32,"numAtRisk":49}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":22,"numAtRisk":49}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":22,"numAtRisk":49}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":55,"numAffected":29,"numAtRisk":49}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":22,"numAtRisk":49}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":49}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":49}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":49}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":49}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":49}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":49}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":34,"numAtRisk":49}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":49}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":28,"numAtRisk":49}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":49}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":49}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":21,"numAtRisk":49}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":49}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":49}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":49}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":49}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":49}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":49}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":49}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":49}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":49}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":49}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":49}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Enrollment was stopped early due to difficulties with patient recruitment. Given the number of missing/unknown tumor assessments, care should be taken when interpreting the primary outcome measure. An identified error was corrected in the results."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"1-800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"D011827","term":"Radiation"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D055585","term":"Physical Phenomena"}]}},"hasResults":true}